DTC
CYTK icon

Deep Track Capital’s Cytokinetics CYTK Stock Holding History

Deep Track Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,347,300
Closed -$112M – 69
2023
Q4 		$112M Buy
+1,347,300
New +$48.8M 3.76% 6

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deep Track Capital's CYTK Position: Q2 2026 in Review

Deep Track Capital reduced its Cytokinetics (CYTK) stake by 49% in Q2 2026, selling an estimated $48.4M and leaving 700,000 shares worth $59.6M. The position accounts for 0.87% of the portfolio, ranked #37.

Deep Track Capital first reported a position in CYTK in Q4 2023 and has held it in 10 quarters since. The position peaked at $236M in Q3 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Deep Track Capital held 700,000 shares of Cytokinetics worth $59.6M as of Q2 2026.
  • Deep Track Capital sold 674,320 Cytokinetics shares in Q2 2026, an estimated $48.4M.
  • Cytokinetics made up 0.87% of Deep Track Capital's portfolio in Q2 2026, its #37 holding.
  • Deep Track Capital first reported a position in Cytokinetics in Q4 2023 and has held it in 10 quarters since.
  • Deep Track Capital's Cytokinetics position peaked at $236M in Q3 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Deep Track Capital's 13F filing for Q2 2026, filed 14 Aug 2026.